Colin Buss is an Associate at Wolf Greenfield, focusing on biotechnology patent matters for clients of all sorts (startups, academic institutions, emerging life sciences companies, etc.). He advises clients on patent application drafting and prosecution, patentability and freedom-to-operate analyses, third-party IP assessments, and broader IP strategy, as well as licensing, collaboration, and other sorts of agreements. Colin’s technical expertise spans immune cell profiling, immunotherapies, nanoparticle synthesis and characterization, primary cell culture, oligonucleotide technologies, antibodies and antibody-drug conjugates, synthetic biology, and various animal models. He has worked with clients in various life sciences areas, including gene therapies, antibodies and antibody-drug conjugates, oligonucleotides and other nucleic acids, nanoparticle delivery technologies, as well as others. He earned his PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences & Technology program, where his research on nanotechnologies for disease diagnosis and treatment included applications in cancer immunotherapy and lung infections, and led to co-invented patent applications. Learn more. 

Jas Lee is a Shareholder at Wolf Greenfield, where she focuses her practice on intellectual property strategy development and execution, including patent portfolio management, U.S. and international patent prosecution, non-infringement and invalidity opinions, agreements and licensing, and IP due diligence. She counsels a wide range of clients—from startups and academic institutions to venture capital firms and global corporations—on complex U.S. and international patent matters. With a broad technical background, Jas brings over a decade of experience in areas such as microfluidics, medical devices and diagnostics, drug delivery, bioreactors, cleantech, electrochemical devices (including lithium batteries), nanotechnology, microfabrication, materials chemistry, organic chemistry, and pharmaceuticals. Learn more.  

Gabe McCool is Counsel at Wolf Greenfield, where he advises life sciences companies on strategic intellectual property design, portfolio development, and transactional matters across the biotechnology and pharmaceutical sectors. He brings a rare hybrid perspective shaped by nearly 25 years in both private practice and in-house leadership roles at venture-backed biotechnology companies.

Recently, Gabe served as VP of Legal & Intellectual Property at ReNAgade Therapeutics, where he helped architect the company’s IP strategy in RNA medicines through its combination with Orna Therapeutics and subsequent multibillion-dollar acquisition by Eli Lilly. His in-house experience informs his approach to IP as a core business asset—aligned with financing strategy, partnerships, competitive positioning, and long-term value creation.

Gabe has counseled organizations at every stage of growth—from academic innovators and early-stage startups to clinical-stage biotech companies and global pharmaceutical organizations—on U.S. and international patent matters, diligence, and strategic portfolio development. His technical background in microbiology, biochemistry, and molecular biology supports his work across genetic medicines, gene and cell therapies, RNA therapeutics, vaccines, drug delivery technologies, and bioprocessing. Learn more.

Jeff joined the Office of the General Counsel in May 2005. Jeff is Chief Patent Counsel for Columbia. His practice encompasses all aspects of patent law, including prosecution, strategic counseling, licensing and post-licensing compliance, litigation, and legislative and regulatory matters. 

Jeff holds an S.B. in physics from MIT; an M.A. and Ph.D. in physics from Stony Brook University; and a J.D. from NYU School of Law. He is admitted to practice law in New York and before the U.S. Patent and Trademark Office.